ArticleEuropean journal of pediatrics2026
Fosfomycin combination therapy in high-risk paediatric patients with multidrug-resistant infections: a retrospective study.
Article in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intravenous fosfomycin is a broad-spectrum, bactericidal antibiotic active against Gram-positive and Gram-negative bacteria, including multidrug-resistant (MDR) strains. Evidence regarding its use in paediatric patients, particularly as part of combination therapy, remains limited. This study aimed to evaluate the safety and clinical outcomes of intravenous fosfomycin-based combination therapy in children. We conducted a single-centre, retrospective study including paediatric patients aged 0-18 years who received IV fosfomycin at Regina Margherita Children's Hospital in Turin between July 2019 and April 2025. Patients with underlying comorbidities, immunosuppression, invasive devices, or prematurity were included. Fifty paediatric patients were enrolled, with a median age of 5.93 years and balanced sex distribution. Comorbidities were present in 80% of cases, and 56% had primary or acquired immunodeficiency. Fosfomycin was always used in combination therapy for confirmed bloodstream infections (54%), osteoarticular infections (12%), skin and soft tissue infections (8%), or other infections (24%). Microbiological identification was achieved in 90% of cases: 53.4% Gram-negative and 46.6% Gram-positive bacteria. Half of the isolated pathogens were MDR, including ESBL, CPE, MDR Pseudomonas aeruginosa, XDR and MDR Gram-positive bacteria. Five patients died, and therapeutic failure-defined as death, relapse, or failure to achieve microbiological clearance-occurred in 28% of cases. IV fosfomycin was well tolerated, and no adverse effects requiring treatment discontinuation were reported. Conclusions: In a cohort of vulnerable paediatric patients with severe underlying conditions and difficult-to-treat infections, IV fosfomycin-based combination therapy was well tolerated and associated with acceptable clinical outcomes. Its use should be considered a rescue therapy for infections resistant to standard treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.